Biomarker Core

西奈山ADRC(SANO)：生物标志岩芯(G芯)--研究综述 生物标志物提供了阿尔茨海默病(AD)病理特征的间接证据，提供了更早的 阿尔茨海默病的诊断和参加针对这些病理的治疗试验的可能性增加 将从干预中受益。生物标记物研究日益必要，以实现双向 翻译努力，以了解疾病的异质性，并确定复原力因素。这个 拟议的Biomarker Core将巩固和支持涉及生物标记物研究的现有努力，目标是 改善早期诊断，确定复原力指标，表征疾病异质性，以及 加快临床试验工作。Biomarker Core的目标是：1)为Biomarker提供服务 收集和分析ADRC队列，并促进ADRD的广泛研究。核心将协调 使用NIH-AA研究框架(A/T/N)对ADRC队列进行生物标记物表征。核心意志 提供特定MRI序列、PET示踪剂和流体生物标记物的采集建议； 分析管道；以及支持项目设计的专业知识。2)通过以下方式促进广泛和快速的共享 与其他核心机构、整个机构以及与外部机构的互动。核心将促进 用于银行和共享处理后的神经成像数据和流体样本的信息学，有助于传递生物标记物- 使参与者参与最匹配的研究和试验，并支持开放科学的文化，以鼓励 跨越机构边界的协作努力。3)利用成像生物标记物数据催化 制定创新项目，重点是将生物标志物作为疾病风险的早期指标并确定其特征 异质性和弹性因素。核心将积极与调查人员合作，以优化纳入 项目中的生物标记物，并将向以生物标记物为特征的参与者提供机会。4)开拓未来 通过生物标记物培训和参与基于项目的活动。核心将提供生物标记物培训 对于REC受训人员和新接触ADRD研究的调查人员，与调查人员协商以制定项目 涉及生物标记物，并将把临床ADRD研究人员与生物标记物方面的技术专长联系起来。穿过这些 AIMS，核心将强调疾病的早期阶段(临床前和轻度认知障碍)，有一个目标 最大化现有观测项目的效用，并增加参与者表征的可能性 将保留在样本中，以便登记进入临床试验。核心将优先处理以下方面的特征 代表少数群体为健康差距研究做出贡献，并增加ADRD的普适性 生物标志物研究。这些核心活动将支持获取、分析、信息学和数据共享，以 将生物标记物研究纳入ADRC的努力，以促进对疾病异质性的了解 通过说明与脆弱性或弹性因素相关的生物学差异，这些因素是 临床症状的表现。

Mount Sinai ADRC (Sano): Biomarker Core (Core G) – Research Summary Biomarkers provide indirect evidence of the pathological hallmarks of Alzheimer's disease (AD), affording earlier diagnosis of AD and increased likelihood that individuals enrolled in therapeutic trials targeting these pathologies will benefit from the intervention. Biomarker research is increasingly necessary for enabling bidirectional translational efforts, for understanding heterogeneity of the disease, and for identifying resilience factors. The proposed Biomarker Core will consolidate and bolster existing efforts involving biomarker research with the goals of improving early diagnosis, identifying indicators of resilience, characterization of disease heterogeneity, and acceleration of clinical trial efforts. The aims of the Biomarker Core are to: 1) Provide services for biomarker collection and analysis on the ADRC cohort and to facilitate ADRD research broadly. The Core will coordinate biomarker characterization of the ADRC cohort using the NIH-AA research framework (A/T/N). The Core will provide recommendations for acquisition with specific MRI sequences, PET tracers, and fluid biomarkers; analytic pipelines; and expertise to support project design. 2) Promote wide and rapid sharing through interactions with other Cores, across the institution, and with outside institutions. The Core will facilitate informatics for banking and sharing processed neuroimaging data and fluid samples, help to route biomarker- characterized participants to best-matched studies and trials, and support a culture of open science to encourage collaborative efforts across institutional boundaries. 3) Leverage imaging biomarker data to catalyze development of innovative projects focused on biomarkers as early indicators of disease risk and to characterize heterogeneity and resilience factors. The Core will actively work with investigators to optimize inclusion of biomarkers in projects and will provide access to biomarker-characterized participants. 4) Develop the future through biomarker training and involvement in project-based activities. The Core will provide biomarker training to REC trainees and to investigators new to ADRD research, consult with investigators to develop projects involving biomarkers, and will link clinical ADRD researchers to technical expertise in biomarkers. Across these aims, the Core will emphasize the early stages of disease (preclinical and mild cognitive impairment), with a goal of maximizing utility to existing observational projects and increasing the likelihood that characterized participants will remain in the sample for enrollment into clinical trials. The Core will prioritize characterization of under- represented minorities to contribute to health disparities research and increase the generalizability of ADRD biomarker research. These Core activities will support acquisition, analysis, informatics, and data sharing to integrate biomarker research into the efforts of the ADRC to accelerate understanding of disease hetereogeneity by illuminating biological differences associated with vulnerability or resilience factors that underlie the expression of clinical symptoms.